XPO1 and plasma cell myeloma: Selective inhibition of XPO1/CRM1 by selinexor (XPOVIO), a small molecule approved for the treatment of relapsed or refractory multiple myeloma in 2019 and relapsed/refractory diffuse large B-cell lymphoma in 2020, and currently under clinical development in a variety of hematological and solid tumors [22], is able to downregulate cytoplasmic survivin expression thus increasing apoptosis of cancer cells [23,24].